Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Meningococcal Vaccine Market, by Brand
1.4.2 North America Meningococcal Vaccine Market, by Type
1.4.3 North America Meningococcal Vaccine Market, by Age Group
1.4.4 North America Meningococcal Vaccine Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Recent Developments in Meningococcal Vaccine Market
Chapter 4. North America Meningococcal Vaccine Market by Brand
4.1 North America Bexsero Market by Country
4.2 North America Trumenba Market by Country
4.3 North America Nimenrix Market by Country
4.4 North America Menactra Market by Country
4.5 North America Menveo Market by Country
4.6 North America Other Brands Market by Country
Chapter 5. North America Meningococcal Vaccine Market by Type
5.1 North America Bivalent Market by Country
5.2 North America Quadrivalent Market by Country
5.3 North America Other Types Market by Country
Chapter 6. North America Meningococcal Vaccine Market by Age Group
6.1 North America Children (2 years & above) and Adults Market by Country
6.2 North America Infants(0 to 2 years) Market by Country
Chapter 7. North America Meningococcal Vaccine Market by Country
7.1 USA Meningococcal Vaccine Market
7.1.1 USA Meningococcal Vaccine Market by Brand
7.1.2 USA Meningococcal Vaccine Market by Type
7.1.3 USA Meningococcal Vaccine Market by Age Group
7.2 Canada Meningococcal Vaccine Market
7.2.1 Canada Meningococcal Vaccine Market by Brand
7.2.2 Canada Meningococcal Vaccine Market by Type
7.2.3 Canada Meningococcal Vaccine Market by Age Group
7.3 Mexico Meningococcal Vaccine Market
7.3.1 Mexico Meningococcal Vaccine Market by Brand
7.3.2 Mexico Meningococcal Vaccine Market by Type
7.3.3 Mexico Meningococcal Vaccine Market by Age Group
7.4 Rest of North America Meningococcal Vaccine Market
7.4.1 Rest of North America Meningococcal Vaccine Market by Brand
7.4.2 Rest of North America Meningococcal Vaccine Market by Type
7.4.3 Rest of North America Meningococcal Vaccine Market by Age Group
Chapter 8. Company Profiles
8.1 GlaxoSmithKline PLC (GSK)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Approvals:
8.2 Pfizer, Inc.
8.2.1 Company Overview
8.2.1 Financial Analysis
8.2.2 Segmental and Regional Analysis
8.2.3 Recent strategies and developments:
8.2.3.1 Approvals:
8.3 Sanofi S.A.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Approvals:
8.4 Walvax Biotechnology Co., Ltd.
8.4.1 Company Overview
8.5 Bio-Manguinhos (Oswaldo Cruz Foundation)
8.5.1 Company Overview
8.5.2 Recent strategies and developments:
8.5.2.1 Partnerships, Collaborations, and Agreements:
8.6 Bio-Med Pvt. Ltd.
8.6.1 Company Overview
8.7 Chongqing Zhifei Biological Products Co., Ltd.
8.7.1 Company Overview
8.8 Hualan Biological Engineering, Inc.
8.8.1 Company Overview
8.9 Incepta Pharmaceuticals Ltd.
8.9.1 Company Overview
8.10. Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)
8.10.1 Company Overview
8.10.2 Recent strategies and developments:
8.10.2.1 Product Launches and Product Expansions:
Unique Offerings 